Haloperidol-induced behavioral supersensitivity is increased by monosialoganglioside treatment in rats without affecting spiroperidol-binding
- PMID: 7996425
Haloperidol-induced behavioral supersensitivity is increased by monosialoganglioside treatment in rats without affecting spiroperidol-binding
Abstract
In rats, dopamine supersensitivity was induced by haloperidol (HAL) treatment for 3 weeks, either by implanted polymer matrices or by daily i.p. injections (1.0 mg/kg/day). Thereafter, dopamine supersensitivity was tested by measurement of motor activity of the animals after application of the dopamine agonist apomorphine (0.5 mg/kg i.p.) and by determination of the specific D2 dopamine binding sites in the corpus striatum by using [3H]spiroperidol. In both modes of HAL administration, no differences were found in the behavioral and neurochemical parameters. The apomorphine-induced motility was enhanced, and the known up-regulation of the striatal D2 dopamine binding was detected. When monosialoganglioside (GM1) was given daily i.p. for 3 weeks parallel to HAL application, dopamine supersensitivity, as indicated by the apomorphine-induced motility, was enhanced significantly without affecting the striatal D2 dopamine receptor up-regulation. In a subsequent experiment, we reduced the HAL dose and observed the expected D2 dopamine up-regulation. However, GM1 had no effect either on striatal D2 dopamine binding or on motility. A thin-layer chromatography analysis revealed that the endogenous gangliosides pattern in the corpus striatum also remained unchanged after HAL treatment. In conclusion, GM1-induced elevation of behavioral supersensitivity cannot be explained by a direct interaction with the D2 dopamine receptor, but other mechanisms may be involved, such as the modification of second messenger pathways.
Similar articles
-
Alterations in striatal neuropeptide Y system activity of rats with haloperidol-induced behavioral supersensitivity.Neuropeptides. 2005 Oct;39(5):515-23. doi: 10.1016/j.npep.2005.04.004. Epub 2005 Sep 9. Neuropeptides. 2005. PMID: 16154634
-
Long-term haloperidol treatment (but not risperidone) enhances addiction-related behaviors in mice: role of dopamine D2 receptors.Addict Biol. 2009 Jul;14(3):283-93. doi: 10.1111/j.1369-1600.2008.00145.x. Epub 2009 Mar 5. Addict Biol. 2009. PMID: 19298320
-
Ganglioside interactions with the dopaminergic system of rats.J Neurosci Res. 1988;19(1):88-93. doi: 10.1002/jnr.490190112. J Neurosci Res. 1988. PMID: 3125345
-
Effects of haloperidol and GM1 ganglioside treatment on striatal D2 receptor binding and dopamine turnover.Life Sci. 1998;62(13):1161-9. doi: 10.1016/s0024-3205(98)00042-3. Life Sci. 1998. PMID: 9519797
-
Dopamine synthesis: tolerance to haloperidol and supersensitivity to apomorphine depend on presynaptic receptors.Adv Biochem Psychopharmacol. 1980;24:17-22. Adv Biochem Psychopharmacol. 1980. PMID: 6996441 Review. No abstract available.
Cited by
-
Residual dopamine receptor desensitization following either high- or low-dose sub-chronic prior exposure to the atypical anti-psychotic drug olanzapine.Psychopharmacology (Berl). 2013 Jan;225(1):141-50. doi: 10.1007/s00213-012-2802-1. Epub 2012 Jul 24. Psychopharmacology (Berl). 2013. PMID: 22825579
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources